Literature DB >> 18682771

Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?

Scott North1.   

Abstract

Entities:  

Year:  2008        PMID： 18682771      PMCID： PMC2494892          DOI： 10.5489/cuaj.602

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  8 in total

Review 1.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.

Authors:  Eric Winquist; Tricia S Kirchner; Roanne Segal; Joseph Chin; Himu Lukka
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

2.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; N Geller; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander
Journal:  Cancer       Date:  1989-12-15       Impact factor: 6.860

3.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

Authors: 
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

4.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

Authors:  H von der Maase; S W Hansen; J T Roberts; L Dogliotti; T Oliver; M J Moore; I Bodrogi; P Albers; A Knuth; C M Lippert; P Kerbrat; P Sanchez Rovira; P Wersall; S P Cleall; D F Roychowdhury; I Tomlin; C M Visseren-Grul; P F Conte
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

5.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

Authors:  C J Logothetis; F H Dexeus; L Finn; A Sella; R J Amato; A G Ayala; R G Kilbourn
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

6.  Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.

Authors:  Marcus L Quek; John P Stein; Peter W Nichols; Jie Cai; Gus Miranda; Susan Groshen; Siamak Daneshmand; Eila C Skinner; Donald G Skinner
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

Review 8.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321
  8 in total
  3 in total

1.  Perioperative chemotherapy for muscle-invasive bladder cancer.

Authors:  Peter Black; Alan So
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

2.  Effect of neoadjuvant chemotherapy on overall survival of patients with T2-4aN0M0 bladder cancer: A systematic review and meta-analysis according to EAU COVID-19 recommendation.

Authors:  Dong Hyuk Kang; Kang Su Cho; Young Joon Moon; Doo Yong Chung; Hae Do Jung; Joo Yong Lee
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.240

3.  Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.

Authors:  Agus Rizal A H Hamid; Fanny Riana Ridwan; Dyandra Parikesit; Fina Widia; Chaidir Arif Mochtar; Rainy Umbas
Journal:  BMC Urol       Date:  2020-10-14       Impact factor: 2.264
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.